載脂蛋白A1(APOA1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Apolipoprotein A1 (APOA1) ,etc. by FLIA (Flow Luminescence Immunoassay)
Apo-A1; ApoA-1 Milano; ProapoA-I; Proapolipoprotein A-I; Truncated apolipoprotein A-I
（注：?jiǎn)未位鞙y(cè)多因子不超過(guò)8個(gè)指標(biāo) ）
- 編號(hào)LMA519Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3.5h
- 檢測(cè)范圍0.39-400ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.13 ng/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 2090 ¥ 2171 ¥ 2291 ¥ 2452 ¥ 2613 ¥ 2854 ¥ 3216 ¥ 4020 添加到價(jià)格計(jì)算器 計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)載脂蛋白A1(APOA1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的載脂蛋白A1(APOA1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 79-104 | 92 |
| EDTA plasma(n=5) | 79-104 | 101 |
| heparin plasma(n=5) | 98-105 | 101 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的載脂蛋白A1(APOA1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中載脂蛋白A1(APOA1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 86-93% | 78-101% | 85-96% | 91-98% |
| EDTA plasma(n=5) | 84-98% | 78-103% | 92-102% | 98-105% |
| heparin plasma(n=5) | 84-104% | 83-90% | 95-104% | 78-98% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠）標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL，
37°C酶標(biāo)板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測(cè)溶液A100μL，37°C酶標(biāo)板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測(cè)溶液B100μL，37°C振動(dòng)孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將載脂蛋白A1(APOA1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠，其中的載脂蛋白A1(APOA1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的載脂蛋白A1(APOA1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的載脂蛋白A1(APOA1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| APA519Hu01 | 載脂蛋白A1(APOA1)活性蛋白 | Cell?culture;?Activity?Assays. |
| APA519Hu61 | 載脂蛋白A1(APOA1)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA519Hu01 | 載脂蛋白A1(APOA1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| EPA519Hu61 | 載脂蛋白A1(APOA1)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA519Hu01 | 載脂蛋白A1(APOA1)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA519Hu71 | 載脂蛋白A1(APOA1)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| MAA519Hu21 | 載脂蛋白A1(APOA1)單克隆抗體 | WB; IHC |
| MAA519Hu24 | 載脂蛋白A1(APOA1)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA519Hu26 | 載脂蛋白A1(APOA1)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA519Hu23 | 載脂蛋白A1(APOA1)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA519Hu25 | 載脂蛋白A1(APOA1)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA519Hu29 | 載脂蛋白A1(APOA1)單克隆抗體 | WB; IHC; ICC; IP. |
| RAA519Hu21 | 載脂蛋白A1(APOA1)重組抗體 | WB; IHC; ICC. |
| RAA519Hu27 | 載脂蛋白A1(APOA1)重組抗體 | WB; IF; ICC; IHC; IP; FCM. |
| MAA519Hu22 | 載脂蛋白A1(APOA1)單克隆抗體 | WB; IHC; ICC; IP. |
| FAA519Hu02 | 抗載脂蛋白A1(APOA1)單克隆抗體 | Flow cytometry. |
| LAA519Hu76 | 載脂蛋白A1(APOA1)單克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| SEA519Hu | 載脂蛋白A1(APOA1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| AEA519Hu | 抗載脂蛋白A1抗體(Anti-APOA1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
| SCA519Hu | 載脂蛋白A1(APOA1)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMA519Hu | 載脂蛋白A1(APOA1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| PSA519Hu01 | 載脂蛋白A1(APOA1)抗體對(duì) | ELISA; CLIA; ELISPOT; Luminex; Immunochromatography and other Immunoassays. |
| KSA519Hu01 | 載脂蛋白A1(APOA1)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| European Journal of Applied Physiology | Endurance training enhances ABCA1 expression in rat small intestine [PubMed: 19629515] |
| Official Journal of the INWR | Effect of eight weeks of wrestling and circuit fitness training on Apo lipoportein A-I and lymphocyte ABCA1 gene expression in well-trained wrestler. [Wrestling: source] |
| Biochemical and Biophysical Research Communications | Treadmill exercise enhances ABCA1 expression in rat liver [ScienceDirect: S0006291X0701488X] |
| World Journal of Sport Sciences | The Effect of Eight Weeks of Wrestling and Wrestling Technique Based Circuit Training on Lymphocyte ABCA1 Gene Expression and Plasma Apolipoprotein A-1 [Idosi: source] |
| Biochimica et Biophysica Acta | Hepatic lipase- and endothelial lipase-deficiency in mice promotes macrophage-to-feces RCT and HDL antioxidant properties [PubMed: 23328279 ] |
| Biomarkers | The association of a distinct plasma proteomic profile with the cervical high-grade squamous intraepithelial lesion of Uyghur women: a 2D liquid-phase chromatography/mass spectrometry study [PubMed: 22458349] |
| Journal of the American Heart Association | MicroRNA-33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE?/? Mice [PubMed: PMC3540673] |
| PLoS ONE | Apolipoprotein AI Is a Potential Mediator of Remote Ischemic Preconditioning [Plosone: Source] |
| Molecular Genetics and Metabolism | DYRK1A overexpression decreases plasma lecithin: cholesterol acyltransferase activity and apolipoprotein AI levels [Pubmed: 23920041] |
| Endocrinology | Deficiency of Clusterin Exacerbates High-Fat Diet-Induced Insulin Resistance in Male Mice [Pubmed: 24684302] |
| Molecular Genetics and Metabolism Reports | Corrective effects of hepatotoxicity by hepatic Dyrk1a gene delivery in mice with intermediate hyperhomocysteinemia [Sciencedirect:S2214426915000026] |
| J Psychopharmacol | Anti-atherogenic properties of high-density lipoproteins in psychiatric patients before and after two months of atypical anti-psychotic therapy [PubMed: 26253619] |
| Biochim Biophys Acta | Culturing of HepG2 cells with human serum improve their functionality and suitability in studies of lipid metabolism [PubMed: 26515253] |
| Pharmacol Res Perspect | Efficacy of tomato concentrates in mouse models of dyslipidemia and cancer [PubMed: 26171234] |
| Clin Exp Nephrol | Differentially expressed urinary biomarkers in children with idiopathic nephrotic syndrome [PubMed: 26351173] |
| Oncogene | Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis [PubMed: 26279300] |
| Oncogene | Apolipoprotein AI inhibits experimental colitis and colitis-propelled carcinogenesis [Pubmed:26279300] |
| Allergy | Serum levels of 9α,11β-PGF2 and apolipoprotein A1 achieve high predictive power as biomarkers of anaphylaxis. [pubmed:28378321] |
| Journal of Chromatography A | Application of a new procedure for liquid chromatography/mass spectrometry profiling of plasma amino acid-related metabolites and untargeted shotgun proteomics to identify mechanisms and biomarkers of calcific aortic stenosis [S0021967317311858] |
| 11 | High-Density Lipoproteins Exert Pro-inflammatory Effects on Macrophages via Passive Cholesterol Depletion and PKC-NF-kB/STAT1-IRF1 Signaling [pubmed:27866837] |
| Biomedical Science Letters | Effect of Ginkgo biloba Extract (EGb 761) on Serum Cholesterol Levels in Wild-type C57Bl/6 Mice [10.15616/BSL.2017.23.2.80] |
| ACS?Biomaterials Science?&?Engineering | Enhanced Antiatherosclerotic Efficacy of Statin-Loaded Reconstituted High-Density Lipoprotein via Ganglioside GM1 Modification [abs:10.1021] |
| Food?Research International | Wild Lonicera caerulea berry polyphenol extract reduces cholesterol accumulation and enhances antioxidant capacity in vitro and in vivo [Pubmed:29580541] |
| Journal of The Science of Food and Agriculture | Consumption of orange fermented beverage improves antioxidant status and reduces peroxidation lipid and inflammatory markers in healthy humans [Pubmed:29124773] |
| Toxicon | A membrane disrupting toxin from wasp venom underlies the molecular mechanism of tissue damage [Pubmed:29654869] |
| European?Journal of Pharmacology | The effect of exenatide (a GLP-1 analog) and sitagliptin (a DPP-4 inhibitor) on plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and concentration in?… [Pubmed: 30768981] |
| European Journal of Preventive Cardiology | High-intensity interval training has a greater effect on reverse cholesterol transport elements compared with moderate-intensity continuous training in obese male rats [Pubmed: 31718266] |
| Diagnostics | Systemic Alterations of Immune Response-Related Proteins during Glaucoma Development in the Murine Model DBA/2J [Pubmed: 32585848] |
| VETERINARY PATHOLOGY | Pathology and Proteomics-Based Diagnosis of Localized Light-Chain Amyloidosis in Dogs and Cats [Pubmed: 32880234] |
| Nat Commun | GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity [34853313] |
| Cardiovasc Toxicol | Interplay of Obesity, Ethanol, and Contaminant Mixture on Clinical Profiles of Cardiovascular and Metabolic Diseases: Evidence from an Animal Study [Pubmed:35429258] |
| Peptides | Neuropeptide Y promotes hepatic apolipoprotein A1 synthesis and secretion through neuropeptide Y Y5 receptor [Pubmed:35660638] |
| Journal of Functional Foods | Castanea mollissima shell polyphenols regulate JAK2 and PPARγ expression to suppress inflammation and lipid accumulation by inhibiting M1 macrophages?… [] |
